COR2ED - Oncology Medical Conversation

Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de detectar alterações genéticas?

Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.

Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de pulmão.

Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de pulmão e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.

Prefere assistir enquanto escuta?

Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmao-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/

Ou veja o vídeo no YouTube: https://youtu.be/lmwt0UVitF4

Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org

Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com

What treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy?  How can we select the right treatment for the right patient? 

Medical oncologists Assoc. Prof. Gerald Prager (Austria) and Dr Victor Hugo Fonseca de Jesus draw from their own clinical expertise and data from clinical trials to provide their perspectives on these questions.  They discuss how to manage side effects from available treatments to maximise survival benefit whilst maintaining quality of life and consider what the future holds for later-line treatment in metastatic colorectal cancer.

Prefer to watch as well as listen?

Watch a video

of the experts in conversation and download the full transcript on the COR2ED

website: https://cor2ed.com/gi-connect/programmes/patient-outcomes-mcrc/

Or go to the video on YouTube: https://youtu.be/ftjskGynDIc

We are pleased to share that this podcast is endorsed by Bayer

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This educational podcast is developed by cor2ed.com

Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are best andwhen should testing be performed?

In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC).

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close collaboration with the pathologist and other members of the multidisciplinary team for optimal patient care.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website:https://cor2ed.com/precision-oncology-connect/programmes/precision-oncology-nsclc/

Or go to the video on YouTube: https://youtu.be/Gn_sjyexreM

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This podcast is developed by cor2ed.com

What are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations?

You are watching part 3 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode, you’ll hear Assoc. Prof. Martina Murphy (medical oncologist) and Assoc. Prof. Caterina Marchiò (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in ovarian cancer.

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in ovarian cancer and discuss best practice approaches to help minimise pre-analytical challenges.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/ovarian-cancer-preanalytical-challenges-biomarker/

Or go to the video on YouTube: https://youtu.be/EabQZ4CKf5s

We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

What are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations?

You are watching part 2 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode, you’ll hear Dr Bruna Pellini (medical oncologist) and Semir Vranić (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in lung cancer.

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in lung cancer and discuss best practice approaches to help minimise pre-analytical challenges.

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/lung-cancer-preanalytical-challenges-biomarker/

Or go to the video on YouTube: https://youtu.be/OG7pWLZ5KMk

We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible.  Do you know how to sequence later line therapies in metastatic colorectal cancer?

In this podcast, gastrointestinal oncologists Dr Thomas Winder (Austria and Switzerland) and Dr Mark Lewis (USA) discuss the treatment of metastatic colorectal cancer, third line and beyond.  They discuss the sequence of later line treatments regorafenib, TAS-102, bevacizumab and fruquintinib and refer to key clinical trials such as SUNLIGHT, CORRECT, RECOURSE, FRESCO-2 and ReDOS.  They emphasise the importance of balancing treatment efficacy whilst considering adverse event profiles to maintain the patient’s quality of life. 

The experts also discuss biomarkers used in a number of molecularly selected trials such as HER2 in the HERACLES (trastuzumab plus lapatininb), MOUNTAINEER (tucatinib plus trastuzumab) and DESTINY-CRC02 (trastuzumab deruxtecan) studies and KRAS G12c in the CODEBREAK 300 study (sotorasib plus panitumumab).

What are tumour agnostic cancer treatments and which biomarkers do they target?

Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast.

As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others.

Listen to deepen your understanding of:

 Prefer to watch as well as listen?

Watch a video of the experts in conversation and get the clinical takeaways and podcast transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/tumour-agnostic-therapies/

Or go to the video on YouTube: https://www.youtube.com/watch?v=AO33Yv0RTVs

Find out more about the experts Prof. David Hong and Dr Tracy L Stockley

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer and is developed by cor2ed.com.

What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?

You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.

In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in prostate cancer and discuss best practice approaches to help minimise pre-analytical challenges.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/prostate-cancer-preanalytical-challenges-biomarker/

Or go to the video on YouTube: https://www.youtube.com/watch?v=Sxzw1SX3nao

We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP) and The National Alliance of State Prostate Cancer Coalitions (NASPCC). You can find out more about AMP at https://amp.org and NASPCC at https://naspcc.org

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics.

This podcast is developed by cor2ed.com.

In this podcast, Prof. Andra H. James (Professor Emeritus of Obstetrics and Gynecology, Division Maternal Fetal Medicine, Duke University Hospital, Durham, North Carolina, US) and Dr Maria Elisa Mancuso (Senior Haematology Consultant at the Center for Thrombosis and Hemorrhagic Diseases of IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy) discuss various treatment options for severe postpartum haemorrhage (also called PPH).

Experts discuss what causes PPH and how to determine the risk before and during labour with algorithms and other helpful tools. The discussion moves to when haematologic expertise is required and how collaboration can be optimized to provide the best care for patients. Furthermore, the experts share their learnings from clinical practice through discussion of specific patient cases, including patients with and without underlying bleeding disorders, as well as where haemostatic agents fit in the protocol.

In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Dr Lars Asmis (Haematologist, University of Zurich, Switzerland) discuss the association between thrombosis and cancer. 

Experts discuss how different tumours affect the risk for thrombosis in patients and genetic disorders such as thrombophilia. They cover multiple scores (Khorana, Vienna, PROTECHT and Pabinger) that might help to categorise thrombosis risk in oncology patients.

The discussion moves to how cancer patients with thrombosis should be treated and the duration of treatment of low molecular weight heparins and direct oral anticoagulants (DOACs), with reference to the CLOT study and recent guidelines. In addition, they discuss whether there should be a different approach with hospital in- and out-patients

 Finally, both experts discuss anticoagulation and oncocardiology and the higher incidences of atrial fibrillation reported in cancer patients.